RxDoctor Payments Data

Sergio Obligado, MD

Nephrology · Goshen, NYNPI 1104035237

Payments from drug & device makers

$3,989in general payments, 2019–2025

Across 155 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$828
  • AstraZeneca$417
  • Otsuka America Pharmaceutical, Inc.$272
  • Amgen$271
  • Novo Nordisk$251
  • Travere Therapeutics, Inc.$251
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,73194%
  • Education$2576%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,989 in reported general payments places this provider in the 70th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$345,659
Medicare patients
707
Services billed
4,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol135$111,242
JardianceEmpagliflozin55$60,526
VelphoroSucroferric Oxyhydroxide14$57,614
JanuviaSitagliptin Phosphate40$41,970
VeltassaPatiromer Calcium Sorbitex35$29,561
KerendiaFinerenone30$27,922
EliquisApixaban24$22,943
Sevelamer Carbonate75$13,237
EntrestoSacubitril/Valsartan18$11,591
MyrbetriqMirabegron12$11,104
LokelmaSodium Zirconium Cyclosilicate14$8,542
Potassium Citrate ErPotassium Citrate88$6,166
Clonidine29$4,702
Febuxostat20$3,005
Valsartan88$2,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$417$119,784149 claims
Boehringer IngelheimJardiance$97$60,52655 claims
BayerKerendia$828$27,92230 claims
NovartisEntresto$124$11,59118 claims
ANI Pharmaceuticals, Inc.Valsartan$45$2,70688 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 nephrology providers in New York.

Other nephrology in Goshen

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →